Zurichâ€Schlieren, July 24, 2015. Molecular Partners AG (ticker: MOLN) today reiterated its commit‐ ment to its un‐partnered pipeline. This includes advancing the clinical and preclinical development pipeline and ramping up the activities in immuno‐oncology. Following Molecular Partners’ expansion of its strategic ophthalmology partnership with Allergan, the company confirmed the discontinuation of the DARPin‐toxin alliance with Roche
Molecular Partners had entered into an oncology alliance with Roche in December 2013. Under this partnership, Roche and Molecular Partners generated DARPin-toxin fusion candidates. Roche is currently terminating its Pseudomonas exotoxin conjugate programs, including antibody and DARPin-based projects. The agreement put in place between Molecular Partners and Roche was specific for the use of DARPins in combination with Pseudomonas exotoxin.
“The DARPin platform generated highly differentiated binders in short time, and it is unfortunate that Roche decided to discontinue these programs for reasons related to the toxin,“ said Christian Zahnd, Chief Executive Officer of Molecular Partners and continued: “We discussed other areas of mutual interest, but given our own proprietary focus on immuno‐oncology, it made no sense to amend the current collaboration. This way, we can avoid working on potentially competing path‐ ways.”
Molecular Partners will evaluate if DARPins from the collaboration will be added to its proprietary pipeline directly or repurposed in other programs.
Molecular Partners is advancing a growing proprietary pipeline of DARPin therapies in oncology. The most advanced systemic DARPin is MP0250 is in Phase 1 clinical studies in solid tumors. MP0250 inhibits both VEGF and HGF from binding to their receptors, thereby blocking tumor growth andÂ tumor spreading. The second most advanced oncology DARPin is MP0274 and has broad anti-HER activity inhibiting both downstream HER2 and HER3-mediated signaling and leading to induction of apoptosis. MP0274 is currently in preclinical development. The current focus of Molecular Partners in research is immuno-oncology.
About Molecular Partners AG
Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new powerful class of therapies known as DARPins. DARPins are potent, specific and versatile small protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen and is backed by established biotech investors. For more information regarding Molecular Partners, go to: www.molecularpartners.com.
For further details, please contact:
-+41 (0)43 344 4242
Dr. Christian Zahnd, CEO
Dr. Patrick Amstutz, COO
Tel: +41 (0) 44 755 77 00
Tel: +44 (0) 208 877 8400 Â Â
This announcement is not an offer to sell, or a solicitation of an offer to purchase, any securities of Molecular Partners AG (the “Company”), nor shall it or any part of it form the basis of, or be relied on in connection with any contract or investment decision. This announcement is not for publication or distribution (directly or indi‐ rectly) in or to the United States, Canada, Australia, Japan or any other jurisdiction in which such distribution would be unlawful.
This announcement contains statements that are, or may be deemed to be, forward‐looking statements. In some case, these forward‐looking statements can be identified by the use of forward‐looking terminology or subjective assessments, including the words “potential”, “expects”, “targets”, “designed”, “intends” or “plans” or comparable terminology or by discussions of plans, objectives, targets, goals, future events or intentions. These forward‐looking statements include matters that are not historical facts or which may not otherwise be provable by reference to past events, and are based on assumptions. By their nature, forward‐looking state‐ ments are subject to known and unknown risks and uncertainties because they relate to events and/or depend on circumstances that may or may not occur in the future. There are a number of factors that could cause ac‐ tual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of the Company cannot be relied on as a guide to future performance.
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the Company nor any other person undertakes any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.